Navigation Links
Innophos Holdings, Inc. Reports First Quarter 2013 Results

CRANBURY, N.J., April 29, 2013 /PRNewswire/ -- Innophos Holdings, Inc. (NASDAQ:  IPHS), a leading international producer of performance-critical and nutritional specialty ingredients, with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets, today announced its financial results for the first quarter 2013.

First Quarter Results

  • Net sales for the first quarter 2013 at $214 million were $14 million below first quarter 2012 primarily on lower GTSP & Other sales. 
  • US/Canada Specialty Phosphates sales were up 7% on growth related to acquisitions. Excluding acquisition benefits, sales were level compared to last year. Strong export sales supporting geographic growth and improved market demand in some areas were offset by significant temporary weakness in several higher margin market segments.
  • Mexico Specialty Phosphates sales declined 24% compared to the year ago period, primarily due to the business experiencing continued variation in manufacturing equipment performance which significantly reduced on-stream time and efficiencies during the quarter. Meaningful progress was made by quarter end in addressing several areas to improve the reliability of the Coatzacoalcos facility.
  • GTSP & Other sales at $24 million for the 2013 first quarter were $11 million below the year ago level primarily on lower volumes.
  • Diluted EPS for the first quarter 2013 was $0.55 compared to $1.22 for the first quarter 2012. GTSP & Other recorded a gain in the current quarter for the finalization of amounts owed on 2005-2008 Mexican water duties below the existing provision, with a benefit of $0.24 per share. This was more than offset by $0.29 per share of elevated costs incurred in cost of goods sold during the current quarter as follows:
  • $0.12 per share from lower efficiencies and unplanned maintenance costs resulting from Mexico production issues;
  • $0.07 per share for an out of period adjustment related to a long term supply agreement;
  • $0.04 per share for a revision of inventory accounting estimates;
  • $0.04 per share related to demurrage on raw material purchases;
  • $0.02 per share for acquisition accounting expenses.
  • The first quarter 2012 results included a $0.32 per share benefit for settlement with former parent, Rhodia, on various claims related to historical amounts owing on Mexican water duties. Giving effect to these adjustments, first quarter 2013 diluted EPS would have been $0.60 compared to $0.90 for the first quarter 2012.  

    Randy Gress, CEO of Innophos, commented on the results, "Our results this quarter, which were not in-line with our long-term objectives, reflected lower demand for some of our higher margin products and operational disruptions at our Mexico facility. Despite these challenges, I remain confident that we are achieving good progress against our strategic growth initiatives. We benefited from strong performance within our nutrition business where our recent acquisitions contributed 5% of overall growth. Our low sodium product line also continued to demonstrate success in the marketplace, doubling sales over the prior year period. In addition, we achieved record export sales from the U.S., including strong results in Asia Pacific, which is particularly encouraging given the investments we have made in China."Mr. Gress continued, "Although overall U.S. & Canada volumes were level with last year, we encountered soft demand in several higher margin market segments. In particular, our industrial asphalt business was affected by extended seasonally cold weather conditions which deferred many infrastructure projects into the second quarter. We also faced a significant decline in export sales to Venezuela as economic instability severely disrupted local supply chains. Sales mix, particularly for our U.S. & Canada business, was therefore unfavorable to margins at both the customer and product level." 

    Mr. Gress added, "Our results during the quarter were also affected by our Mexico operations suffering from various equipment performance and maintenance issues.  As a result, our Coatzacoalcos facility experienced reduced production volumes, lower efficiencies and incurred higher maintenance expenses. The issues largely arose in areas already targeted for improvement in our long term upgrade plan for the facility. As a result, we have accelerated our upgrade program with several important improvements completed during the quarter that have already resulted in improved operating performance, with further upgrades to follow in the second quarter. Our long-term plan for this facility remains critical to our efforts in the region, and we are confident these actions will substantially improve manufacturing reliability and performance going forward."

    Mr. Gress concluded, "I am confident that we will overcome these temporary hurdles and get our business back on track in the next quarter as we have consistently done since the formation of Innophos.  We remain well-positioned to generate above market revenue growth as our strategic growth initiatives continue to gain traction. In the face of significant variation across our end markets, particularly in the U.S., we believe most of the factors that affected our margins during the quarter are temporary and, therefore, we expect to see improvements in the second quarter and throughout the remainder of 2013."Segment Results first quarter 2013 versus 2012 Specialty PhosphatesSpecialty Phosphates sales revenue was down 1% year-over-year on lower sales in Mexico.  US/Canada volumes were up 7% on acquisitions. Mexico volumes were significantly affected by low production levels due to equipment reliability issues. 

    Operating income at $11 million was $22 million below first quarter 2012 levels. The first quarter 2012 had a net benefit of $6 million ($8 million benefit in U.S. and $2 million expense in Mexico) from a delay in the realization of raw material inflation in cost of goods sold that only became fully realized beginning in the second quarter 2012. Operating Income in the first quarter 2013 included $8 million of elevated cost of goods sold of which $3 million related to Mexico manufacturing issues, $2 million was for an out of period adjustment related to a long term supply agreement, $1 million related to a revision of inventory accounting estimates, $1 million was for demurrage on raw material purchases and $1 million was for acquisition accounting expenses.  Operating income margin for first quarter 2013 was 6%, down 1,140 basis points from 2012 levels.  Adjusted for the noted elevated costs, operating income margin would have been 10%.

    US/CanadaUS/Canada Specialty Phosphates sales increased 7% for the first quarter 2013 compared to the year ago period on growth from acquisitions.  Excluding acquisitions, sales were flat with the year ago period, with sales mix skewed towards lower margin products and customers, thus affecting overall margin performance.  

    For the first quarter 2013, operating income of $11 million was $16 million below the year ago quarter.  Excluding the effects noted above for the $8 million advantaged cost of goods sold in the prior period and the $5 million of elevated costs in the U.S. for the current quarter, the decline was $3 million, arising primarily from the lower margin sales mix. Operating income margin was 7% for the first quarter 2013, down 1,210 basis points from the year ago period. Adjusting for the noted elevated costs, operating income margin would have been 11%.

    MexicoFirst quarter 2013 sales were down 24% against the first quarter 2012 due to equipment reliability issues suffered in the quarter which limited production and, therefore, sales.  Volumes were down 19%. Despite these challenges, the business continued to experience strong demand for its more differentiated products and achieved record production in Specialty Ingredients produced at Coatzacoalcos.

    Continued price increase success resulted in improved pricing on most product lines; however, pricing on the less differentiated detergent grade products was moderately lower. This, combined with a price reset on a long term contract, contributed to an overall price decline of 5%.

    Operating income at $1 million for first quarter 2013 was down $6 million from first quarter 2012 levels with lower sales and $3 million of higher costs from reduced efficiencies and higher plant maintenance contributing to the shortfall. Operating income margin was 2% for the 2013 first quarter, down 1,060 basis points from the year ago quarter.  Adjusting for the noted elevated costs, operating income margin would have been 9%.GTSP & OtherGTSP & Other sales (primarily Granulated Triple Superphosphate fertilizer co-product) decreased 31% for the first quarter 2013 compared to the similar period of 2012, with volumes down 27% and prices down 4%.  Market prices are at their seasonal lows just slightly below year ago levels. The volume variance is within the normal quarter to quarter order pattern variation typical for this segment.

    For the first quarter 2013, GTSP & Other recorded $6 million of operating income, up $2 million from the year ago period with both periods recording a $7 million benefit related to Mexican water duties.  Without this benefit and $1 million of higher costs from reduced efficiencies and higher plant maintenance, operating income remained near break-even. Operating income margins were 26% for the first quarter 2013 compared to 13% for the first quarter 2012.  Excluding the noted benefits and elevated costs, operating income margin was 1% for the first quarter 2013, up 840 basis points from the year ago period. 

    Recent Trends and OutlookMarket demand was flat for the first quarter 2013, with a strong start to the quarter offset by a weak finish that particularly affected higher margin market segments. We continue to expect only modest market growth in 2013.

    Momentum behind our growth strategy continues to improve, as evidenced by record export sales from the U.S. for the first quarter 2013, particularly to Asia Pacific and Europe.  Our recently granted food manufacturing license in Taicang, China allows us to begin operations there and build on a strong start to the year in that zone. 

    We continue to expect growth in Specialty Phosphates for the second half of 2013 excluding the benefit of recent acquisitions, to be within our 4-6% long-term target range. For the second quarter, the improvement seen towards the end of the first quarter in Mexico manufacturing performance gives us confidence the impact of production restrictions will be significantly reduced. However, there may be some residual effect in the second quarter as we continue to implement our long-term equipment upgrade program, so while we anticipate good sequential sales improvement, second quarter volumes for Mexico Specialty Phosphates are likely to be moderately lower than the year ago level with a price variance similar to that seen in the first quarter. We are targeting continued improvement in U.S. and Canada volumes and expect this to offset the Mexico volume decline in comparison to the second quarter last year.

    Strong performance by our recent acquisitions is expected to continue, and this, together with the full year benefit of the two acquisitions made in 2012, is expected to contribute an additional 5% revenue growth for the full year 2013 in comparison to 2012.

    We do not expect any major change in raw material purchase prices or underlying selling prices through the second quarter 2013.

    Specialty Phosphates operating income margins are expected to improve significantly in the second quarter on a sequential basis, with further sequential improvement in the third quarter anticipated. The key drivers to the sequential improvement are expected to be an improvement in Mexico production reliability and a strong recovery in demand for the higher margin products that experienced a weak first quarter. With a more typical US/Canada business mix and improved Mexico production performance, Specialty Phosphates operating income margins are expected to improve to the original, full year goal of 15% by the third quarter.

    For the short-term, GTSP is expected to continue near break-even through the second quarter. Fertilizer prices have been at their seasonal lows, with only a modest uptick over the last month, and still remain modestly below prior year levels. 

    The business continues to generate strong cash flow and net debt decreased by $21 million in the 2013 first quarter to $128 million as a result of reduced working capital in Mexico.

    Capital Expenditures Capital expenditures were $7 million in the first quarter 2013, a bit below the expected trendline based on our indicated 2013 expectation of $40-45 million, primarily due to some expenditures accelerated into the fourth quarter 2012.  We expect expenditures to increase in the coming quarters to keep in line with the noted expectation for the year.  Investment continues to be focused on capacity enhancements for US/Canada and Mexico Specialty Ingredients facilities, expanding geographically and enhancing Mexico's capability to process multiple grades of rock, consistent with the Company's supply chain diversification strategy. 

    About Innophos Holdings, Inc.Innophos is a leading international producer of performance-critical and nutritional specialty ingredients, with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets. Innophos combines more than a century of experience in specialty phosphate manufacturing with a growing capability in a broad range of other specialty ingredients to supply a product range produced to stringent regulatory manufacturing standards and the quality demanded by customers worldwide. Innophos is continually developing new and innovative specialty ingredients addressing specific customer applications and supports these high-value products with industry-leading technical service.  Headquartered in Cranbury, New Jersey, Innophos has manufacturing operations in Nashville, TN; Chicago Heights, IL; Chicago (Waterway), IL; Geismar, LA; Ogden, UT; North Salt Lake, UT; Paterson, NJ; Green Pond, SC; Port Maitland, ON (Canada); Taicang (China); Coatzacoalcos, Veracruz and San Jose de Iturbide (Mission Hills), Guanajuato (Mexico). For more information please visit 'IPHS-G'

    Financial Tables FollowInnophos Holdings, Inc.FTI Consulting, Inc.Investor Relations: (609) 366-1299Bryan Armstrong/Matt (212) 850-5600 Conference Call DetailsThe conference call is scheduled for Tuesday, April 30, 2013 at 10:00 am ET and can be accessed by dialing 888-206-4065(U.S.) or 630-827-5974 (international) and entering passcode 34744744.  Please dial in approximately 15 minutes ahead of the start time to ensure timely entry to the call.  A replay will be available between 1:00 pm ET on April 30 and 1:00 pm ET on May 14, 2013.  The replay is accessible by dialing 888-843-7419 (U.S.) or 630-652-3042 (international) and entering passcode 6861213#.

    Safe Harbor for Forward-Looking and Cautionary Statements
    This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended.  As such, final results could differ from estimates or expectations due to risks and uncertainties, including but not limited to: incomplete or preliminary information; changes in government regulations and policies; continued acceptance of Innophos' products and services in the marketplace; competitive factors; technological changes; Innophos' dependence upon first-party suppliers; and other risks.  For any of these factors, Innophos claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, as amended.

    Summary Profit & Loss Statement – First QuarterINNOPHOS HOLDINGS, INC. AND SUBSIDIARIESCondensed Consolidated Statement of Operations (Unaudited)(Dollars In thousands, except per share amounts or share amounts)Three months endedThree months endedMarch 31,March 31,20132012Net sales

    $214,441$228,252Cost of goods sold

    177,407172,384Gross profit

    37,03455,868Operating expenses:
    Selling, general and administrative

    Research & development expenses

    Total operating expenses

    19,10917,729Operating income

    17,92538,139Interest expense, net

    1,1521,627Foreign exchange loss (gain)

    (498)(291)Income before income taxes

    17,27136,803Provision for income taxes

    4,8689,215Net income

    $12,403$27,588Diluted Earnings Per Participating Share

    $0.55$1.22Diluted weighted average common shares outstanding:

    22,326,41822,699,745Dividends paid per share of common stock

    $0.35$0.25Dividends declared per share of common stock


    Segment Reporting – First QuarterThe Company reports its operations in three segments: Specialty Phosphates US & Canada, Specialty Phosphates Mexico and GTSP & Other.  The primary performance indicators for the chief operating decision maker are sales and operating income, with sales on a ship-from basis.  Sales on a ship-from basis are on the same revenue recognition as a ship-to basis and are recognized when delivery has occurred and title and risk of loss passes to the customer.  The following table sets forth the historical results of these indicators by segment:Three months endedThree months endedMarch 31,March 31,Net Sales20132012% ChangeSegment Net SalesSpecialty Phosphates US & Canada

    $150,991$141,5946.6%Specialty Phosphates Mexico

    38,91650,928-23.6%Total Specialty Phosphates

    189,907192,522-1.4%GTSP & Other


    $214,441$228,252-6.1%Segment Operating IncomeSpecialty Phosphates US & Canada

    $10,792$27,236Specialty Phosphates Mexico

    6566,262Total Specialty Phosphates

    11,44833,498GTSP & Other (a)


    $17,925$38,139Segment Operating Income %  of net salesSpecialty Phosphates US & Canada

    7.1%19.2%Specialty Phosphates Mexico

    1.7%12.3%Total Specialty Phosphates

    6.0%17.4%GTSP & Other (a)


    8.4%16.7%Depreciation and amortization expenseSpecialty Phosphates US & Canada

    $7,107$5,371Specialty Phosphates Mexico

    1,7583,772Total Specialty Phosphates

    8,8659,143GTSP & Other


    $9,386$10,239(a) The three month period ended March 31, 2013 includes a $7.2 million benefit to earnings for the
    settlement of Mexican CNA Water Tax Claims owed for the periods 2005 - 2008.  The three month

    period ending March 31, 2012 includes a $7.1 million benefit to earnings related to a settlement

    with Rhodia on their liability for the charges to be paid for Mexican CNA Water Tax Claims.

    Price / Volume – First Quarter The Company calculates pure selling price dollar variances as the selling price for the current year to date period minus the selling price for the prior year to date period, and then multiplies the resulting selling price difference by the prior year to date period volume.  The current quarter selling price dollar variance is derived from the current quarter year to date selling price dollar variance less the previous quarter year to date selling price dollar variance.  The selling price dollar variance is then divided by the prior period sales dollars to calculate the percentage change.  Volume variance is calculated as the total sales variance minus the selling price variance and refers to the revenue effect of changes in tons sold at the relative prices applicable to the variation in tons, otherwise known as volume/mix.

    The following tables illustrate for the three months ended March 31, 2013 the percentage changes in net sales by reportable segments and by Specialty Phosphates product lines compared with the same period of the prior year, including the effect of selling price and volume/mix changes upon revenue:Reportable SegmentsPriceVolume/MixTotalSpecialty Phosphates US & Canada

    -0.5%7.1%6.6%Specialty Phosphates Mexico

    -4.5%-19.1%-23.6%Total Specialty Phosphates

    -1.6%0.2%-1.4%GTSP & Other


    -2.1%-4.0%-6.1%Note: Includes AMT/Triarco benefit of 7.1% in Specialty Phosphates US & Canada 
    Volume/Mix and 5.3% in Total Specialty Phosphates Volume/Mix
    Specialty Phosphates Product LinesPriceVolume/MixTotalSpecialty Ingredients

    -2.8%7.7%4.9%Food & Technical Grade PPA

    2.0%-5.9%-3.9%STPP & Detergent Grade PPA

    -1.2%-28.8%-30.0%Note: Includes AMT/Triarco benefit of 7.9% in Specialty Ingredients Volume/Mix 

    Summary Cash Flow Statement INNOPHOS HOLDINGS, INC. AND SUBSIDIARIESCondensed Consolidated Statements of Cash Flows (Unaudited)(Dollars in thousands)Three months endedThree months endedMarch 31,March 31,20132012Cash flows from operating activities
    Net income

    Adjustments to reconcile net income to net cash
    provided from operating activities:

    Depreciation and amortization

    Amortization of deferred financing charges

    Deferred income tax provision (benefit)

    Share-based compensation

    Changes in assets and liabilities:

    Increase in accounts receivable

    Decrease in inventories

    Decrease in other current assets

    Increase (decrease) in accounts payable

    Decrease in other current liabilities

    Changes in other long-term assets and liabilities

    Net cash provided from operating activities

    35,55629,860Cash flows from investing activities:
    Capital expenditures

    Net cash used for investing activities

    (7,437)(5,200)Cash flows used for financing activities:
    Long-term debt borrowings

    Long-term debt repayments

    Excess tax benefits from exercise of stock options

    Common stock repurchases

    Dividends paid

    Net cash used for financing activities

    (28,743)634Net change in cash

    (624)25,294Cash and cash equivalents at beginning of period

    26,81535,242Cash and cash equivalents at end of period


    Summary Balance Sheets INNOPHOS HOLDINGS, INC. AND SUBSIDIARIESCondensed Consolidated Balance Sheets (Unaudited)(Dollars In thousands)March 31,

    2013December 31,

    2012ASSETSCurrent assets:
    Cash and cash equivalents

    Accounts receivable, net


    Other current assets

    Total current assets

    362,758383,716Property, plant and equipment, net


    83,87983,879Intangibles and other assets, net

    Total assets

    $718,818$739,266LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:
    Current portion of long-term debt

    Accounts payable, trade and other

    Other current liabilities

    Total current liabilities

    85,43286,515Long-term debt

    150,000172,000Other long-term liabilities

    Total liabilities

    Total stockholders' equity

    Total liabilities and stockholders' equity


    Additional Information
    Net debt is a supplemental financial measure that is not required by, or presented in accordance with, USGAAP.  The Company believes net debt is helpful in analyzing leverage and as a performance measure for purposes of presentation in this release. The Company defines net debt as total long-term debt (including any current portion) less cash and cash equivalents.


    SOURCE Innophos Holdings, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Innophos CFO To Present At 2013 Sidoti Emerging Growth Conference
    2. Innophos Holdings, Inc. Announces Annual Meeting
    3. Innophos Holdings, Inc. Reports Fourth Quarter And Full Year 2012 Results
    4. Innophos Holdings, Inc. Schedules Call to Discuss Fourth Quarter And Full Year 2012 Results
    5. Innophos To Present At 2012 KeyBanc Capital Markets Basic Materials & Packaging Conference
    6. Zimmer Holdings, Inc. Reports First Quarter 2013 Financial Results
    7. Hill-Rom Holdings, Inc. to Host Investor Conference May 7
    8. Hill-Rom Holdings, Inc. Hosts Fiscal 2013 Second Quarter Earnings Conference Call and Webcast
    9. Organovo Holdings, Inc. Announces Change of Fiscal Year
    10. PDP Holdings, LLC Announces Support for Health and Human Services Office of Inspector General Guidance
    11. Mr. William Lerner, Esq. nominated to the Board of Directors of Sanomedics International Holdings, Inc.
    Post Your Comments:
    (Date:10/11/2017)... PARK, Calif. , Oct. 11, 2017  BioPharmX ... national scientific team that developed an innovative way to ... quantity of the delivery of new drugs. ... 2017 Fall Clinical Dermatology Conference will show how researchers ... General Hospital, Harvard Medical School used a suite of ...
    (Date:10/10/2017)... COUNTY, Calif. , Oct. 10, 2017  NDS received FDA ... Mobile  — a medical-grade battery-powered display stand specifically designed for endoscopy ... to transform technology into a clinical solution to support the improvement ... Innovative Design ... ZeroWire Mobile Wireless Solution ...
    (Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
    (Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
    (Date:10/12/2017)... New Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... fitness centers in the U.S., announced today its plans to open a flagship location ... club will occupy the former Rooms To Go store next to Office Depot in ...
    (Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...
    Breaking Medicine News(10 mins):